During the past decade, Retina Associates of St. Louis conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Retina Associates of St. Louis" are "Macular Degeneration" (1 trials), "Macular Edema" (1 trials), "Neovascular Age-related Macular Degeneration" (1 trials), "Retinal Vein Occlusion" (1 trials) and "Wet Macular Degeneration" (1 trials). Many other conditions were trialed in "Retina Associates of St. Louis" in a lesser frequency.

Most popular intervention types in "Retina Associates of St. Louis" are "Drug" (4 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Faricimab" (2 trials), "Sham Procedure" (2 trials), "Aflibercept" (1 trials), "Lucentis or Avastin" (1 trials) and "rhuFab V2 (ranibizumab)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Retina Associates of St. Louis" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Retina Associates of St. Louis". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Retina Associates of St. Louis, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Associates of St. Louis, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".